论文部分内容阅读
目的 回顾性分析经动脉灌注健择 (盐酸吉西他滨 )治疗中晚期胰腺癌临床疗效。方法 13例中晚期胰腺癌患者接受动脉灌注健择治疗。治疗后观察肿瘤改善情况及临床受益反应 (CBR)。结果 PR 1例 ( 7 7% ) ,NC 3例 ( 2 3 % ) ,SD 3例 ( 2 3 % ) ,6例无法评价。Kaplan Meier法计算 6个月累积生存率为 46 88% ,频数分布法计算中位生存期为 5 5个月 ,中位进展期为 2 6 9个月。临床受益率为 30 76 % (与文献相比P <0 0 0 1)。结论 无论对于初治或化疗无效的病人 ,动脉灌注健择均显示出良好的临床受益反应 ;并能有效延长病人的生存时间
Objective To retrospectively analyze the clinical effect of transarterial infusion of gemcitabine (gemcitabine hydrochloride) in the treatment of advanced pancreatic cancer. Methods Thirteen patients with advanced pancreatic cancer received arterial infusion of gemcitabine. After treatment, the tumor improvement and clinical benefit response (CBR) were observed. Results PR 1 (7 7%), NC 3 cases (23%), SD 3 cases (23%), 6 cases can not be evaluated. Kaplan-Meier calculated a 6-month cumulative survival rate of 46 88%. The median survival time was 55 months using the frequency distribution method, with a median progression of 269 months. The clinical benefit rate was 30.76% (P <0.01 compared with the literature). CONCLUSIONS: Arterial infusion of Gemcitabine shows a good clinical benefit response to both untreated and chemotherapy-ineffective patients and can effectively prolong the patient’s survival time